HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advocates For Switching Birth Control Pill Face Social, Risk Obstacles

This article was originally published in The Tan Sheet

Executive Summary

A women's health advocacy group that hopes to meet with FDA within the next year to explore potentially switching oral contraceptives to OTC may be hard-pressed to find a pharmaceutical company interested in sponsoring such a venture

You may also be interested in...

Benefits, Pitfalls Of OTC Birth Control Apparent In Cross-Border Study

A pair of reports from a study of women who accessed birth control pills over the counter or by prescription showcases the benefits and challenges inherent in nonprescription oral contraceptives.

FDA Scientists Say Plan B Decision-Makers At CDER “Should Be Removed”

A group of FDA scientists is calling for the removal of agency leaders who are suspected of politically motivated decisions regarding the emergency contraceptive Plan B

People In Brief

Perrigo promotes in pricing, planning


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts